According to Zacks Research, CVS Health (CVS) is currently a more attractive value stock than Danaher (DHR). CVS holds a Zacks Rank of #2 (Buy) compared to DHR's #3 (Hold), and CVS boasts a Value grade of A based on metrics like a forward P/E ratio of 9.98 and a PEG ratio of 0.87, while DHR has a Value grade of D with a forward P/E of 23.97 and a PEG ratio of 2.54.
Within the Medical Services sector, CVS Health (CVS) presents a more compelling value proposition compared to Danaher (DHR), according to a Zacks Research analysis. CVS holds a Zacks Rank of #2 (Buy), signifying an improving earnings outlook driven by positive estimate revisions, whereas DHR carries a Zacks Rank of #3 (Hold). This distinction is further supported by their Style Scores, with CVS earning an A for Value, contrasted with DHR's D grade. Key valuation metrics underscore this difference: CVS exhibits a forward P/E ratio of 9.98, a PEG ratio of 0.87, and a P/B ratio of 1.0. In comparison, DHR's metrics are notably higher, with a forward P/E of 23.97, a PEG ratio of 2.54, and a P/B ratio of 2.60. These quantitative indicators, combined with the positive earnings trajectory for CVS, lead to the assessment that CVS is currently the superior value option between the two.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
